RESEARKA

The synthesis identified two observational cohorts examining colchicine's impact on inflammatory and immune biomarkers. Shi 2026 was an observational pilot study in adults with heart failure with preserved ejection fraction (HFpEF) who received colchicine 0.5 mg once daily, with inflammatory markers reassessed after two weeks of outpatient treatment. Pourkarim 2025 described a study protocol for a randomized, double-blind, placebo-controlled trial examining colchicine in sepsis, a life-threatening condition with high mortality rates of up to 40% due to multiple organ dysfunction, enrolling a total of 44 patients aged 18 to 80 years. Both sources contributed to the immune inflammation outcome class, though neither constituted a completed clinical RCT with hard endpoints. The evidence base for this outcome class therefore rests on indirect directness assessments and observational designs.

Citation Support

• source_1 Mohammadnia 2025
• source_2 Li 2025
• source_3 Ammirati 2026
• source_4 Pascart 2026
• source_5 Broekhoven 2022